Search

Copyright of Journal of Uludag University Medical Faculty / Uludağ Üniversitesi Tıp Fakültesi Dergisi is the property of Journal of Uludag University Medical Faculty and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objectives: The main goal of the study was to investigate how pregabalin (PGB) affects proinflammatory cytokine release in patients with fibromyalgia syndrome (FMS). Patients and methods: This experimental research study was conducted with 85 female participants (mean age: 49.6±10.1 years; range, 30 to 73 years) between April 2020 and November 2020. Of the participants, 30 were FMS patients using PGB 150 mg/day for at least three months, 30 were FMS patients not using PGB, and 25 were healthy individuals. The detection of FMS was carried out according to the 2010 American College of Rheumatology diagnostic criteria. Levels of proinflammatory cytokines (interleukin [IL]-2, IL-6, IL-12, IL-17, interferon-gamma, and tumor necrosis factor-alpha) were measured by enzyme-linked immunosorbent assay. Results: Serum concentrations of proinflammatory cytokines were remarkably decreased in FMS patients using PGB (p<0.001) and were higher in patients with FMS not using PGB than in healthy subjects (p<0.001). The highest values of proinflammatory cytokines were found in the group of FMS patients not using PGB (p<0.001). Conclusion: These results indicate that PGB inhibits the release of proinflammatory cytokines, suggesting that it can be used as an anti-inflammatory agent in inflammatory cases. [ABSTRACT FROM AUTHOR]

Objectives: This study aimed to investigate the physical and emotional effects of the coronavirus disease 2019 pandemic in patients with fibromyalgia syndrome (FMS) and chronic low back pain (CLBP) patients. Patients and methods: The cross-sectional controlled study was performed with 1,360 participants (332 males, 1,028 females; mean age: 42.3±12.5 years; range, 18 to 65 years) between September 2020 and February 2021. The participants were evaluated in three groups: the FMS group (n=465), the CLBP group (n=455), and the healthy control group (n=440). Physical activity, pain levels, and general health status before and during the pandemic were evaluated in all participants. Stress levels were analyzed with the perceived stress scale (PSS) in all groups, and disease activity was analyzed with the fibromyalgia impact questionnaire (FIQ) in patients with FMS. Results: Patients with FMS had worsened general health status and pain levels during the pandemic compared to the other groups (p<0.01). The FMS group showed significantly higher PSS scores than those in other groups (p<0.01). There was a weak-positive correlation between FIQ and PSS parameters in patients with FMS (p<0.05, r=0.385). Conclusion: The general health status, pain, and stress levels of the patients with FMS and CLBP tended to worsen during the pandemic. This high-stress level appeared to affect disease activity in patients with FMS. [ABSTRACT FROM AUTHOR]

Amaç: Romatoid artrit (RA) hastalarında yeni bir enflamatuvar belirteç olan sistemik immün enflamasyon indeksi [SII (Platelet sayısı×nötrofil sayısı/lenfosit sayısı)] ile hastalık aktivitesi arasındaki ilişkiyi değerlendirmeyi amaçladık. Yöntem: Tek merkezli kesitsel bir çalışma olarak planladığımız çalışmamıza 18-65 yaş arası 104 RA hastası ve 43 sağlıklı gönüllü olmak üzere toplam 147 katılımcı dahil edildi. Katılımcıların klinik, laboratuvar ve demografik özellikleri kaydedildi. RA hastalarını, hastalık aktivite skoru 28-eritrosit sedimentasyon hızına (DAS28-ESR) göre <2,6 olanları remisyonda RA (n=51) ve >2,6 olanları aktif RA (n=53) olmak üzere iki gruba ayırdık. SII'nin C-reaktif protein (CRP), eritrosit sedimentasyon hızı (ESR), DAS28-ESR, basitleştirilmiş hastalık aktivite indeksi (SDAI) ve klinik hastalık aktivite indeksi (CDAI) ile korelasyonlarını belirlemek için Spearman korelasyon analizini kullandık. Aktif RA grubu ile remisyon RA grubu karşılaştırıldığında, SII ve diğer değişkenlerin hastalık aktivitesini değerlendirmedeki etkinliğini belirlemek için ROC (alıcı işlem karakteristikleri, receiver operating characteristic) eğrisi analizi kullanıldı. Bulgular: RA grubunda sağlıklı kontrollere göre nötrofil düzeyleri daha yüksek, lenfosit düzeyleri ise daha düşüktü (her ikisi için p<0,05). Platelet (PLT) değerleri açısından gruplar arasında anlamlı fark yoktu (p=0,095). Aktif RA grubunda nötrofil, PLT, CRP, ESR, DAS28-ESR, SDAI ve CDAI değerleri remisyondaki RA hastalarına göre daha yüksekti (p<0,05). Lenfosit değerleri açısından ise gruplar arasında anlamlı farklılık saptanmadı (p=0,089). SII, hem RA grubunda sağlıklı kontrollere göre, hem de aktif RA grubunda remisyondaki RA grubuna göre daha yüksek ve istatistiksel olarak anlamlıydı (her ikisi için p<0,001). SII değeri, CRP (rs: 0,627, p<0,001), ESR (rs: 0,383, p<0,001), DAS28-ESR (rs: 0,775, p<0,001), SDAI (rs: 0,796, p<0,001) ve CDAI (rs: 0,798, p<0,001) ile pozitif korelasyon gösterdi. RA hastalık aktivitesini belirlemek için optimal kesme noktası 479,36 (×109/L) [eğri altındaki alan (EAA): 0.968, %95 güven aralığı (GA): 0,914-0,993, duyarlılık: %92,45, özgüllük: %86,27]. Sonuç: SII, RA hastalık aktivitesini değerlendirmek için etkili ve ucuz yeni bir yöntem olabilir. [ABSTRACT FROM AUTHOR]

Copyright of Istanbul Medipol Üniversitesi Hukuk Fakültesi Dergisi is the property of Istanbul Medipol University and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)